Covid-19: From Bench to Bedside by Barh, Debmalya

Covid-19: From Bench to Bedside (Paperback) (ISBN-13: 9781032040622)

Vendor: Debmalya Barh
Product type: Books
Format: Paperback
$94.95
$94.95
$94.95
Subtotal: $94.95
Covid-19: From Bench to Bedside by Barh, Debmalya

Covid-19: From Bench to Bedside

$94.95
Covid-19: From Bench to Bedside by Barh, Debmalya

Covid-19: From Bench to Bedside

$94.95
Format: Paperback
Description
Description
x

The COVID-19 pandemic has affected the entire world in an unprecedented way, and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-CoV-2 drug strategies, including repurposing drugs used for other indications and the development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials.

Key Features

  • Explains the background of the COVID-19 pandemic, the current progress in the development of treatments and prevention of COVID-19 including future aspects of dealing with the pandemic

  • Serves as a timely repository of knowledge on COVID-19 for researchers and medical professionals engaged in its management



Author: Debmalya Barh
ISBN-10: 1032040629
ISBN-13: 9781032040622
Publisher: CRC Press
Language: English
Published: 03/04/2022
Pages: 222
Format: Paperback
Weight: 0.93lbs
Size: 10.00h x 7.00w x 0.51d
By Debmalya Barh
By Debmalya Barh
x

Dr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) at the Department of Genetics, Ecology and Evolution, Institute of Biological Sciences (ICB), Federal University of Minas Gerais (UFMG), Brazil. He is also an honorary Scientist at Institute of Integrative Omics and Applied Biotechnology (IIOAB), India.

Dr. Kenneth Lundstrom is currently the CEO of PanTherapeutics in Lausanne, Switzerland.He serves on editorial boards of various journals including Biomedicines and Viruses, and acts as Editor-in-chief for Frontiers in Translational Virology.

Recently Viewed Products